Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).
The European Myelofibrosis Network (EUMNET), a European research network on myelofibrosis with myeloid metaplasia (MMM), has developed a definition of response for the disease by using clinicohematologic, histologic, and cytogenetic criteria. A core set of 5 clinicohematologic criteria was selected out of 9 candidates on the basis of their sensitivity to change measured in 196 patients treated either during clinical trials or routine clinical practice. A consensus panel of 16 international experts was convened and asked to score the level of response in 104 patient profiles as major, moderate, minor, or no response according to changes of the clinicohematologic criteria. Using the experts' consensus as the gold standard, the performance of 100 possible definitions of response was evaluated. Criteria for major or moderate clinicohematologic response were determined to be changes in hemoglobin (Hb) and spleen size and the presence of constitutional symptoms, while changes in platelet count and white blood cell (WBC) count served as complementary criteria and were of value for defining minor responses. A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM.
Barosi
Giovanni
G
Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S. Matteo, Viale Golgi 19, 27100 Pavia, Italy. barosig@smatteo.pv.it
Bordessoule
Dominique
D
Briere
Jean
J
Cervantes
Francisco
F
Demory
Jean-Loup
JL
Dupriez
Brigitte
B
Gisslinger
Heinz
H
Griesshammer
Martin
M
Hasselbalch
Hans
H
Kusec
Rajko
R
Le Bousse-Kerdiles
Marie-Caroline
MC
Liberato
Nicola L
NL
Marchetti
Monia
M
Reilly
John T
JT
Thiele
Jurgen
J
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D005060:Europe; D006405:Hematology / Q000379:methods / Q000592:standards; D006801:Humans; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*